Release issued 24th October 2007

Results of Clinical Phase I Study Presented at US Conference

Lund, Sweden, October 24, 2007 - Active Biotech AB (OMX Nordic:ACTI) has presented the final results of the previously reported clinical Phase I study of the cancer project ANYARA in combination with Taxotere® in patients with non-small cell lung cancer.

 

The presentation was made at the AACR-NCI-EORTC1) conference "Molecular Targets and Cancer Therapeutics" in San Francisco, USA.

 

The results2) show that ANYARA can be given safely in combination with Taxotere® (Sanofi-Aventis), an established drug for the treatment of non-small cell lung cancer.

 

Thirteen patients with advanced non-small cell lung cancer were included in the study. Observed side effects during ANYARA treatment were expected and included transient fever, hypotension and nausea. Other toxicities recorded in the study were typical of Taxotere®. Out of ten evaluable patients, two received a partial response (a tumor reduction of at least 30 percent), including one patient that had previously failed with Taxotere® treatment and 5 patients had stable disease.

 

ANYARA is presently developed primarily for the treatment of Renal Cancer and a pivotal phase II/III is ongoing with an interim analysis planned for mid 2008.

 

 

Active Biotech AB (publ)

 

Sven Andréasson

President and CEO  

 

1) American Association for Cancer Research - National Cancer Institute - European Organization for Research and Treatment of Cancer

 

2) View the complete poster "An open label phase I study of ABR-217620 in combination with docetaxel in patients with NSCLC" at www.activebiotech.com

 

For further information, please contact

Sven Andréasson, President & CEO

+46 (0)46 19 20 49

sven.andreasson@activebiotech.com

 

Tomas Leanderson, Chief Scientific Officer

+46 (0)46 19 20 95

tomas.leanderson@activebiotech.com

(13th May 2008) Active Biotech advances ANYARA into Phase III clinical trial.

(15th April 2008) Preclinical data presented for Active Biotech's ANYARA technology

(10th August 2007) FDA Approves IND for Phase II Studies of TASQ

(26th July 2007) EMEA Grants Orphan Drug Status to Active Biotech's Cancer Treatment ANYARA

(9th June 2007) Positive Clinical Data for TASQ - Active Biotech's Novel Treatment of Prostate Cancer